Breaking News

Biohaven Wins FDA Approval for NURTEC ODT

Developed in partnership with Catalent using its Zydis orally disintegrating tablet (ODT) technology

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Biohaven Pharmaceutical Holding Co. received approval from the U.S. FDA for NURTEC ODT (rimegepant) for the acute treatment of migraine in adults. NURTEC ODT has been developed in partnership with Catalent using its Zydis orally disintegrating tablet (ODT) technology to create a freeze-dried tablet that disperses almost instantly in the mouth without water. NURTEC ODT is the first and only calcitonin gene-related peptide (CGRP) receptor antagonist available in a fast-acting ODT. Zydis technol...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters